-
Sector Analysis
Ovarian Cancer - Cell and Gene Therapies 15-Market Assessment and Forecast to 2031
Ovarian Cancer–Cell and Gene Therapies 15-Market Report Overview The total market value for the 15M, which includes both CGTs and established/traditional ovarian cancer therapies was $3.2B in 2021. The increasing number of ovarian cancer cases will drive market growth during the forecast period. Ovarian Cancer–Cell and Gene Therapies 15-Market Outlook, 2021-2031 ($ Billion) Buy the Full Report to Know More about the Ovarian Cancer–Cell and Gene Therapies 15-Market Forecast Download a Free Report Sample The ovarian cancer–cell and gene therapies...
-
Sector Analysis
Myelofibrosis Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2031
Myelofibrosis Market Report Overview The myelofibrosis market size was $2.39 billion across the 8MM in 2021 and will achieve a CAGR of more than 1% during 2021-2031. The approvals of several late-stage pipeline agents especially Vonjo and momelotinib and the continued strong performance of Jakafi/Jakavi in the first-line setting will drive market growth during the forecast period. Myelofibrosis Market Outlook, 2021-2031 ($ Billion) Buy the Full Report to Gain More Information on the Myelofibrosis Market Forecast Download a Free Report...
-
Product Insights
Post-Polycythemia Vera Myelofibrosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Post-Polycythemia Vera Myelofibrosis Clinical Trials Market Report Overview The post-polycythemia vera myelofibrosis (PPV-MF) clinical trial market research report provides an overview of PPV-MF clinical trials scenario. The report provides top-line data relating to the clinical trials on PPV-MF. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
-
Product Insights
Acute Myelocytic Leukemia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Acute Myelocytic Leukemia Clinical Trials Market Report Overview A total of 4,834 Acute Myelocytic Leukemia clinical trials were conducted as of March 2023. The Acute Myelocytic Leukemia clinical trial report provides a comprehensive understanding of the Acute Myelocytic Leukemia clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key...
-
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) - Cell and Gene Therapies 15-Market Assessment and Forecast to 2031
Non-Small Cell Lung Cancer (NSCLC)–Cell and Gene Therapies 15-Market Report Overview The total market value for the 15M, which includes both CGTs and established/traditional NSCLC therapies was $30.7 billion in 2021. A high level of unmet need in the second and third line, especially in the PD-L1-negative setting will significantly drive the uptake and usage of novel CGT thereby propelling the market growth. Non-Small Cell Lung Cancer (NSCLC)–Cell and Gene Therapies 15-Market Outlook, 2021-2031 ($ Billion) Buy the Full Report...
-
Sector Analysis
Head and Neck Squamous Cell Carcinomas (HNSCC) - Cell and Gene Therapies 15-Market Assessment and Sales Forecast to 2031
Head and Neck Squamous Cell Carcinomas (HNSCC) Market Report Overview The total head and neck squamous cell carcinomas market value for the 15M, which includes both cell and gene therapies and established/traditional HNSCC therapies was $1.9 billion in 2021. The following are some of the key highlights of the HNSCC market: The market growth is attributed to the established immune checkpoint inhibitors having a high ACOT. APAC had the highest share in 2021. Head and Neck Squamous Cell Carcinomas (HNSCC)...
-
Sector Analysis
Glioblastoma Multiforme (GBM) - Cell and Gene Therapies 15-Market Assessment and Sales Forecast to 2031
Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market Report Overview The total market value for the 15M, which includes both CGTs and established/traditional GBM therapies was $630 million in 2021. High usage of dendritic cell vaccines and oncolytic viruses that demonstrate significant survival advantages will drive market growth during the forecast period. Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market Outlook, 2021-2031 ($ Billion) Buy the Full Report to Know More about the Glioblastoma Multiforme (GBM) – Cell...
-
Product Insights
Neuroblastoma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Neuroblastoma Clinical Trials Market Report Overview There were a total of 680 neuroblastoma clinical trials conducted as of January 2023. The neuroblastoma clinical trial market research report provides a comprehensive overview of the market across regions and countries (G7 & E7). It also provides insights into the various phases, trial status, and end points status. The report includes information about the sponsor types and the prominent sponsors associated with the trials as well. Neuroblastoma Clinical Trials Market Segmentation by Regions...
-
Sector Analysis
B-Cell Non-Hodgkin Lymphoma (NHL) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
B-Cell Non-Hodgkin Lymphoma (NHL) Marketed and Pipeline Drugs Market Report Overview B-cell NHL generally arises in the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen, and can disseminate to involve distant sites such as the lung or brain in the later stages of the disease. NHLs are further categorized into indolent or aggressive prognostic subtypes, which further influence outcomes and treatment decisions. The B-Cell NHL marketed, and pipeline drugs market research report includes an assessment of...
-
Sector Analysis
Acute Lymphocytic Leukemia (ALL) - Cell Therapies 15-Market Assessment and Sales Forecast to 2031
Acute Lymphocytic Leukemia Cell Therapy Market Overview The total market value for the 15M, which includes both cell therapies and established/traditional ALL therapies was $2.3 billion in 2021. The need for “off-the-shelf” products with lower costs and reduced infrastructure requirements raises the development of allogeneic agents thereby driving the market growth. Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Outlook, 2021-2031 ($ Billion) Buy the Full Report to Know More about the Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.